Why the study?
Although saline infusion and captopril challenge tests are routinely used to confirm primary aldosteronism, their side effects and complications have not been systematically studied.
Does the captopril challenge test have a lower rate of side effects compared to the saline infusion test in patients with suspected primary aldosteronism?
Does the captopril challenge test have a lower rate of side effects compared to the saline infusion test in patients with suspected primary aldosteronism?
The captopril challenge test is associated with a substantially lower rate of side effects compared to the saline infusion test, making it a safer confirmatory option for primary aldosteronism, especially in severely hypertensive patients.
Answers are grounded in this paper and cite their sources.
Documents common side effects during pre-test medication adjustment for suspected PA; leaves open whether test-specific monitoring guidelines require updating.
OBJECTIVE: Saline infusion test (SIT) and captopril challenge test (CCT) are standard confirmatory procedures routinely used in the diagnostic work-up of primary aldosteronism (PA). However, side effects and complications during testing have not been systematically studied. DESIGN: We performed a cohort study with patients undergoing SIT and/or CCT in two centers from 2016 until 2018. METHODS: We studied 272 study participants with suspected PA enrolled at two outpatient centers in Germany. We assessed the frequency and severity of side effects during adjustment of blood pressure medication and during SIT and CCT. RESULTS: During the adjustment phase prior confirmatory testing, side effects including palpitations, headaches, edema and hypertensive episodes occurred in 18.4% of study participants. Side effects were associated with higher defined daily doses (DDD) (r = 0.25, P < 0.005), number of antihypertensive drugs (r = 0.285, P < 0.005) and higher blood pressure (r = 0.145, P = 0.019). During SIT, 17.5% of study participants had side effects, associated with higher blood pressure (systolic: r = 0.541, P < 0.0005; diastolic: r = 0.426, P < 0.0005) and DDDs (r = 0.727, P < 0.0005). During CCT, only 1.5% of study participants developed side effects. CONCLUSIONS: In contrast to the high rate of side effects during SIT, CCT appears to be the safer test with a very low event rate. This makes CCT especially suitable for severely hypertensive patients.
No takes yet. Share an insight, caveat, or question.
Heinrich et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: